177 related articles for article (PubMed ID: 23828279)
1. Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma.
Zhang JP; Lee EQ; Nayak L; Doherty L; Kesari S; Muzikansky A; Norden AD; Chen H; Wen PY; Drappatz J
J Neurooncol; 2013 Oct; 115(1):71-7. PubMed ID: 23828279
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma.
Raizer JJ; Rademaker A; Evens AM; Rice L; Schwartz M; Chandler JP; Getch CC; Tellez C; Grimm SA
Cancer; 2012 Aug; 118(15):3743-8. PubMed ID: 22179954
[TBL] [Abstract][Full Text] [Related]
3. Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial.
Dietrich J; Versmee L; Drappatz J; Eichler AF; Nayak L; Norden A; Wong E; Pisapia MR; Jones SS; Gordon AB; Chabner BA; Hochberg F; Batchelor TT
Oncologist; 2020 Sep; 25(9):747-e1273. PubMed ID: 32520407
[TBL] [Abstract][Full Text] [Related]
4. [Curative effect of pemetrexed on the treatment of relapsed primary central nervous system lymphoma].
Wang Y; Wang X; Zhao Y; Tao R; Zhu Y; Zhao R; Xu J
Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):46-9. PubMed ID: 24602732
[TBL] [Abstract][Full Text] [Related]
5. Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy.
Zhang Y; Zhao L; Huang P; Wu J; Wang F; Huang Y; Zhang L
Cancer Chemother Pharmacol; 2012 Oct; 70(4):611-5. PubMed ID: 22903536
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial.
Socinski MA; Raju RN; Neubauer M; Smith DA; Richards DA; Savin M; Ruxer RL; Reynolds CH; Zhan F; Bromund JL; Chen R; Obasaju C
J Thorac Oncol; 2008 Nov; 3(11):1308-16. PubMed ID: 18978567
[TBL] [Abstract][Full Text] [Related]
7. Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series.
Chamberlain MC
J Neurooncol; 2014 May; 118(1):155-62. PubMed ID: 24584709
[TBL] [Abstract][Full Text] [Related]
8. High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma.
Chamberlain MC
J Neurooncol; 2016 Feb; 126(3):545-50. PubMed ID: 26563190
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Fan Y; Huang ZY; Yu HF; Luo LH
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases.
Kumthekar P; Grimm SA; Avram MJ; Kaklamani V; Helenowski I; Rademaker A; Cianfrocca M; Gradishar W; Patel J; Mulcahy M; McCarthy K; Raizer JJ
J Neurooncol; 2013 Apr; 112(2):247-55. PubMed ID: 23354655
[TBL] [Abstract][Full Text] [Related]
11. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed for Recurrent Primary Central Nervous System Lymphoma in the Elderly: Results of a Retrospective Study.
Xiao J; Wang S; Xu B; Yu L; Han Y
J Healthc Eng; 2022; 2022():8963547. PubMed ID: 35392141
[TBL] [Abstract][Full Text] [Related]
13. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.
Hainsworth JD; Cebotaru CL; Kanarev V; Ciuleanu TE; Damyanov D; Stella P; Ganchev H; Pover G; Morris C; Tzekova V
J Thorac Oncol; 2010 Oct; 5(10):1630-6. PubMed ID: 20802351
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study.
Jalal S; Ansari R; Govindan R; Bhatia S; Bruetman D; Fisher W; Masters G; White A; Stover D; Yu M; Hanna N;
J Thorac Oncol; 2009 Jan; 4(1):93-6. PubMed ID: 19096313
[TBL] [Abstract][Full Text] [Related]
15. Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.
Patrij K; Reiser M; Wätzel L; Pels H; Kowoll A; Herrlinger U; Engert A; Linnebank M; Schackert G; Vogt-Schaden M; Egerer G; Lamprecht M; Batchelor TT; Schlegel U; Schmidt-Wolf IG;
Ger Med Sci; 2011; 9():Doc11. PubMed ID: 21698087
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate re-challenge for recurrent primary central nervous system lymphoma.
Pentsova E; Deangelis LM; Omuro A
J Neurooncol; 2014 Mar; 117(1):161-5. PubMed ID: 24481997
[TBL] [Abstract][Full Text] [Related]
17. Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
del Rio MS; Choquet S; Hoang-Xuan K; Glaisner S; Fourme E; Janvier M; Soussain C
J Neurooncol; 2011 Nov; 105(2):409-14. PubMed ID: 21656329
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS
Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial.
Goedhals L; van Wiyk AL; Smith BL; Fourie SJ
Int J Gynecol Cancer; 2006; 16(3):1172-8. PubMed ID: 16803502
[TBL] [Abstract][Full Text] [Related]
20. [Pemetrexed alone versus pemetrexed combined with oxaliplatin as salvage therapy in stage IV lung adenocarcinoma].
Liu Y; Jiang Y; Gao Z; Wang X; Han B; Jiang L
Zhongguo Fei Ai Za Zhi; 2011 Sep; 14(9):704-9. PubMed ID: 21924035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
